NAD+ Injection Side Effects: What Is Common and What Is Not
Most of what is written about NAD+ side effects was written about IV drips, and most of it is about the drip. The chest tightness, the wave of nausea, the cramping that people describe from an NAD+ infusion are real, and they are largely a function of how quickly a large amount of NAD+ arrives in the bloodstream. The subcutaneous injection we prescribe delivers a smaller amount, more slowly, and has a different — milder — profile. This page separates the two, because a person reading IV horror stories before their first injection is reading about a different experience.
The main page covers what NAD+ is and what the evidence says it does. This page is only about what it feels like and what to do if it feels wrong.
Why the effects follow the speed
NAD+ is a large, charged molecule that does not simply diffuse into cells. Given intravenously, it appears to act on receptors and pathways at the blood-vessel and gut level before it goes anywhere else, and the response — flushing, a sense of pressure in the chest, nausea, abdominal cramping — arrives within minutes and tracks the infusion rate closely. Slow the drip and the symptoms ease; speed it up and they return. That pattern is consistent enough across clinics and the small published studies that it is treated as a property of rapid delivery rather than of NAD+ itself.
A subcutaneous injection into the fat under the skin is absorbed over hours rather than minutes. The same molecule, the same body, a much gentler curve. The IV-specific symptoms are therefore uncommon with the injection, and when they occur they are mild.
What is common with the injection
Local reactions. Redness, tenderness, a small firm area or a bruise where the needle went in. This is the most frequently reported effect, it is the same for most subcutaneous injections, and it resolves on its own. Rotating where you inject reduces it; the main page covers the practical side of self-administration.
Mild flushing or warmth. Some people feel a brief flush or warmth in the face and upper body within the first half-hour. It passes.
Mild nausea. Less common than with IV, usually brief, and more likely if the injection is given on an empty stomach or shortly after alcohol.
Fatigue or a "heavy" feeling the same day, reported by a minority, particularly in the first weeks. It is the opposite of what people expect from an energy-associated treatment, and it usually settles.
Headache. Occasional, mild, and usually within the first few days.
None of these is a reason to stop. All of them are worth mentioning at review, because a pattern of them is the kind of thing a clinician adjusts for.
What belongs mostly to IV drips
Chest tightness or pressure, a racing or pounding heart, marked abdominal cramping, sweating, and the "I need this to stop" feeling that infusion patients describe — these are the rapid-delivery effects. They can occur with the injection but are rare, and when they do occur they are typically brief. They are also the reason we prefer the injection for home use: an infusion that produces them needs someone in the room to slow it down, and a home injection does not have that option, so it is given by a route that does not tend to need it.
What to stop for
Any of the following, with the injection, is a stop-and-message: a rash or hives that spreads beyond the site of the injection; swelling of the lips, face or throat, or any difficulty breathing (this is an emergency — call 911 first); chest pain that does not pass within minutes; a reaction at the site that is hot, spreading and increasingly painful over a day or more, which may be an infection rather than irritation; or symptoms that are getting worse with each injection rather than settling.
True allergic reactions to NAD+ are rare, and the more likely culprit in a reaction is a preservative or excipient in the compounded product — which is one reason your clinician will want to know exactly what happened and when.
Who should be more careful
People with a history of significant heart rhythm problems, because of the rapid-delivery effects on heart rate; people with severe liver or kidney disease, because NAD+ metabolism runs through both; anyone pregnant or breastfeeding, for whom there is no safety data; and people on a long medication list, because NAD+ has not been studied for interactions and the honest position is that we do not know. These are the questions on the assessment. They are not necessarily exclusions; they are reasons for the clinician to think before prescribing rather than after.
Frequently asked questions
Most often a local reaction where the needle went in — redness, tenderness, bruising. Less often mild flushing, brief nausea, same-day fatigue or a headache. The dramatic effects described for IV NAD+ are uncommon with the injection.
Because a large amount arrives in the blood quickly. The symptoms track the infusion rate and ease when it is slowed. The subcutaneous injection is absorbed over hours and rarely produces them.
The short-term safety record is reassuring — small trials and wide clinical use with mostly mild, self-limiting effects. Long-term safety data do not exist, and we say so on the main page.
Brief, mild nausea is not a reason to stop; mention it at review. Nausea that is severe, worsening, or paired with chest pain or breathing difficulty is a reason to stop and contact us — or 911 if breathing is affected.
Rarely, and the compounded product's excipients are a more likely cause than NAD+ itself. Spreading rash, facial or throat swelling, or breathing difficulty is an emergency.
Anyone pregnant or breastfeeding; people with serious heart rhythm, liver or kidney disease need a specific clinical decision. Tell us at assessment.
Where this fits in your plan
The NAD+ Injection page covers the treatment and its evidence; this page is what to expect from the needle. Side effects are asked about at every review.
We measure first. Then we act.
References
- Grant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience 2019;11:257.
- Braidy N et al. Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: rationale, efficacy, safety, and novel therapeutic approaches. Antioxidants & Redox Signaling 2019;30:251–294.
- Conlon N, Ford D. A systems-approach to NAD+ restoration. Biochemical Pharmacology 2022;198:114946.
- Radenkovic D, Reason, Verdin E. Clinical evidence for targeting NAD therapeutically. Pharmaceuticals 2020;13:247.
- Back toNAD+ Injection
- NAD+ and alcoholNAD+ is sold for hangovers and "alcohol detox" on the strength of real biochemistry and no trials. What alcohol does to NAD+, what the marketing extrapolates from it, and what we will not claim.Read
- NAD+ for brain fogThe mouse studies are striking and the human trials are small. What NAD+ has actually been shown to do for cognition, what "brain fog" usually is, and where NAD+ sits once the reversible causes are checked.Read
- NAD+ explainedWhat NAD+ is, why it declines with age, the delivery options, and an honest look at the energy and cellular-health claims for adults over 45.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.
If you have difficulty breathing or swelling of the face or throat, call 911.